Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy

International Journal of Cancer

Volumn 118, Issue 3, 2006, Pages 755-764

  Zaman, Khalil ^a,b   Driscoll, Robert ^a,b   Hahn, Diane ^c   Werffeli, Patricia ^a,b   Goodman, Simon L ^c   Bauer, Jean ^a   Leyvraz, Serge ^a   Lejeune, Ferdy ^a   Stupp, Roger ^a   Rüegg, Curzio ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^c MERCK KGAA   (Germany)

Author keywords

Angiogenesis; Chemotherapy; Predictive; Surrogate markers; TNF

Indexed keywords

ANGIOPOIETIN RECEPTOR; C REACTIVE PROTEIN; FIBRONECTIN; GELATINASE B; INTERLEUKIN 8; MELPHALAN; RECOMBINANT GAMMA INTERFERON; TASONERMIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ADULT; ANGIOGENESIS; ANGIOSARCOMA; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; COLORECTAL CANCER; CONSERVATIVE TREATMENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMICOLECTOMY; HUMAN; ISOLATED LIMB PERFUSION; LIMB PERFUSION; LIPOSARCOMA; MALE; MASTECTOMY; MELANOMA; PRIORITY JOURNAL; SARCOMA; SYNOVIAL SARCOMA; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASMS, DUCTAL, LOBULAR, AND MEDULLARY; NEOVASCULARIZATION, PATHOLOGIC; SARCOMA; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 30444434565     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21408     Document Type: Article

References (62)

1. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Cancer Biol 1992;3:65-71.
2. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, et al. Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
3. Ruegg C, Meuwly JY, Driscoll R, Werffeli P, Zaman K, Stupp R. The quest for surrogate markers of angiogenesis: a paradigm for translational research in tumor angiogenesis and anti-angiogenesis trials. Curr Mol Med 2003;3:673-91.
4. Libutti SK, Choyke P, Carrasquillo JA, Bacharach S, Neumann RD. Monitoring responses to antiangiogenic agents using noninvasive imaging tests. Cancer J Sci Am 1999;5:252-6.
5. Sheen-Chen S, Chen H, Eng H, Sheen C, Chen W. Serum levels of matrix metalloproteinase 2 in patients with breast cancer. Cancer Lett 2001;173:79-82.
6. Zucker S, Lysik R, Zarrabi M, Moll U. M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res 1993;53:140-6.
7. Harris A, Reusch P, Barleon B, Hang C, Dobbs N, Marme D. Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 2001;7:1992-7.
8. Hu Q, Dey A, Yang Y, Shen Y, Jilani I, Estey E, Kantarjian H, Giles F, Albitar M. Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer 2004;100:1884-91.
9. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
10. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207-25.
11. Ziche M, Sorriso C, Parenti A, Brogelli L, Tricarico C, Villari D, Pazzagli M. Biological parameters for the choice of antiangiogenic therapy and efficacy monitoring. Int J Biol Markers 1999;14:214-7.
12. George D, Halabi S, Shepard T, Vogelzang N, Hayes D, Small EJ, Kantoff PW, Cancer and Leukemia Group B 9480. Prognostic significance of vascular endothelial growth factor levels in patients with hormone-refractory prostate cancer treated on Cancer and Leukemia Group B9480. Clin Cancer Res 2001;7:1932-6.
13. Ranuncolo S, Armanasco E, Cresta C, Bal De Kier Joffe E, Puricelli L. Plasma MMP-9 (92 kDa-MMP) activity is useful in the follow-up and in the assessment of prognosis in breast cancer patients. Int J Cancer 2003;106:745-51.
14. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-83.
15. Rafii S, Lyden D, Benezra R, Hattori K, Heissig B. Vascular and hematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nat Rev Cancer 2002;2:826-35.
16. Sato Y, Kanno S, Oda N, Abe M, Ito M, Shitara K, Shibuya M. Properties of two VEGF receptors, Flt-1 and KDR, in signal transduction. Ann N Y Acad Sci 2000;902:201-5.
17. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-71.
18. Jones N, Dumont DJ. Tek/Tie2 signaling: new and old partners. Cancer Metastasis Rev 2000;19:13-7.
19. Bergers G, Brekken R, McManon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
20. Castellani P, Viale G, Dorcaratto A, Nicolo G, Kaczmarek J, Querze G, Zardi L. The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 1994;59:612-8.
21. Astrof S, Crowley D, George EL, Fukuda T, Sekiguchi K, Hanahan D, Hynes RO. Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis. Mol Cell Biol 2004;24:8662-70.
22. Lin Y, Huang R, Chen L, Li S, Shi Q, Jordan C, Huang RP. Identification of interleukin-8 as estrogen receptor-regulated factor involved in breast cancer invasion and angiogenesis by protein arrays. Int J Cancer 2004;109:507-15.
23. Haraguchi M, Komuta K, Akashi A, Matsuzaki S, Furui J, Kanematsu T. Elevated IL-8 levels in the drainage vein of resectable Dukes' C colorectal cancer indicate high risk for developing hepatic metastasis. Oncol Rep 2002;9:159-65.
24. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004;6:447-58.
25. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004;291:585-90.
26. Nozoe T, Matsumata T, Kitamura M, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg 1998;176:335-8.
27. Alexandrakis MG, Passam FH, Boula A, Christophoridou A, Aloizos G, Roussou P, Kyriakou DS. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Hematol 2003;82:19-23.
28. Alexandrakis MG, Passam FH, Sfiridaki K, Moschandrea J, Pappa C, Liapi D, Petreli E, Roussou P, Kyriakou DS. Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival. Leuk Res 2004;28:259-66.
29. Lejeune FJ, Ruegg C, Lienard D. Clinical applications of TNF-alpha in cancer. Curr Opin Immunol 1998;10:573-80.
30. Lejeune F, Kroon B, Di Filippo F, Hoekstra H, Santinami M, Lienard D, Eggermont A. Isolated limb perfusion: the European experience. Surg Oncol Clin N Am 2001;10:821-32.
31. Sipos B, Hahn D, Carceller A, Piulats J, Hedderich J, Kalthoff H, Goodman SL, Kosmahl M, Kloppel G. Immunohistochemical screening for beta-integrin subunit expression in adenocarcinomas using a novel monoclonal antibody reveals strong upregulation in pancreatic ductal adenocarcinomas in vivo and in vitro. Histopathology 2004;45:226-36.
32. Mehta RJ, Diefenbach B, Brown A, Cullen E, Jonczyk A, Gussow D, Luckenbach GA, Goodman SL. Transmembrane-truncated alphav-beta3 integrin retains high affinity for ligand binding: evidence for an 'inside-out' suppressor? Biochem J 1998;330:861-9.
33. Gunsilius E, Petzer A, Stockhammer G, Nussbaumer W, Schumacher P, Clausen J, Gastl G. Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 2000;58:169-74.
34. Barleon B, Sozzani S, Zhou D, Weich H, Mantovani A, Marme D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor Flt-1. Blood 1996;87:3336-43.
35. Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, Shipley J, Senior R, Shibuya M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002;2:289-300.
36. Hiratsuka S, Minowa O, Kuno J, Noda T, Shibuya M. Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. Proc Natl Acad Sci USA 1998;95:9349-54.
37. Toi M, Bando H, Ogawa T, Muta M, Hornig C, Weich H. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int J Cancer 2002;98:14-8.
38. Quinn MJ, Cox D, Foley JB, Fitzgerald DJ. Glycoprotein IIb/IIIa receptor number and occupancy during chronic administration of an oral antagonist. J Pharmacol Exp Ther 2000;295:670-6.
39. Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, Sheppard D, Hynes RO, Hodivala-Dilke KM. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med 2002;8:27-34.
40. Munshi NC, Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 2001;28:565-9.
41. Alexandrakis MG, Passam FH, Dambaki C, Pappa CA, Stathopoulos EN. The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma. J Clin Pathol 2004;57:856-60.
42. George J, Goldstein E, Abashidze S, Deutsch V, Shmilovich H, Finkelstein A, Herz I, Miller H, Keren G. Circulating endothelial progenitor cells in patients with unstable angina: association with systemic inflammation. Eur Heart J 2004;25:1003-8.
43. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, Badiwala MV, Mickle DA, Weisel RD, Fedak PW, Stewart DJ, Kutryk MJ. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 2004;109:2058-67.
44. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 2002;106:913-9.
45. Jin HY, Lee KS, Jin SM, Lee YC. Vascular endothelial growth factor correlates with matrix metalloproteinase-9 in the pleural effusion. Respir Med 2004;98:115-22.
46. Hayashibara T, Yamada Y, Onimaru Y, Tsutsumi C, Nakayama S, Mori N, Miyanishi T, Kamihira S, Tomonaga M, Malta T. Matrix metalloproteinase-9 and vascular endothelial growth factor: a possible link in adult T-cell leukaemia cell invasion. Br J Haematol 2002;116:94-102.
47. Wang H, Keiser JA. Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of Fit-1. Circ Res 1998;83:832-40.
48. Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, Fidler I. Contribution of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst 2002;94:1134-42.
49. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti G, Giavazzi R. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Res 2003;63:5224-9.
50. George M, Eccles S, Tutton M, Abulafi A, Swift R. Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelets scavenging. Clin Cancer Res 2000;6:3147-52.
51. Chin K, Greenman J, E. G, Kumar H, Topping K, Monson J. Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998;4:1279-85.
52. Dirix L, Vermeulen P, Hubens G, I. B, Martin M, C. DP, Van Oosterom A. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumor growth kinetics in advanced colorectal cancer. Ann Oncol 1996;7:843-8.
53. Wu Y, Saldana L, Chillar R, Vadgama J. Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment. Int J Oncol 2002;20:509-16.
54. Karayiannakis A, Syrigos K, Zbar A, Baibas N, Polychronidis A, Simopoulos C, Karatzas G. Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery. Surgery 2002;131:548-55.
55. Salven P. High pre-treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small cell lung cancer. Int J Cancer 1998;79:144-6.
56. Chin K, Greenman J, Gardiner E, Kumar H, Topping K, Monson J. Pre-operative serum vascular endothelial growth factor can select patients for adjuvant treatment after curative resection in colorectal cancer. Br J Cancer 2000;83:1425-31.
57. Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin Cancer Res 2004;10:3110-6.
58. Lin S, Wang Y, Sheu W. Preoperative plasma concentrations of vascular endothelial growth factor and matrix metalloproteinase 9 are associated with stage progression in papillary thyroid cancer. Clin Endocrinol (Oxf) 2003;58:513-8.
59. Lejeune F, Pujol N, Lienard D, Mosimann F, Raffoul W, Genton A, Guillou L, Landry M, Chassot P. Chiolero R, Bischof-Delaloye A, Leyvraz S, et al. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol 2000:669-78.
60. Gerain J, Lienard D, Pampallona S, Baumgartner M, Ruegg C, Buurman WA, Eggermont A, Lejeune F. Systemic release of soluble TNF receptors after high-dose TNF in isolated limb perfusion. Cytokine 1997;9:1034-42.
61. Schienk S, Lienard D, Gerain J, Baumgartner M, Lejeune FJ, Chiquet-Ehrismann R, Ruegg C. Rapid increase in plasma tenascin-C concentration after isolated limb perfusion with high-dose tumor necrosis factor (TNF), interferon gamma (IFN gamma) and melphalan for regionally advanced tumors. Int J Cancer 1995;63:665-72.
62. Barthel H, Wilson H, Collingridge DR, Brown G, Osman S, Luthra SK, Brady F, Workman P, Price PM, Aboagye EO. In vivo evaluation of [18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography. Br J Cancer 2004;90:2232-42.